Jaguar Health unit Napo sponsors pediatric intestinal failure panel as crofelemer studies continue

• Jaguar Health’s Napo unit outlined progress in studies of oral crofelemer for pediatric intestinal failure tied to MVID or SBS-IF.
• Results were already presented in June 2026 at an ESPGHAN meeting from ongoing investigational use in children treated for over a year.
• Studies showed meaningful reductions in dependence on parenteral support, without notable clinical or laboratory safety concerns.
• Program timeline points to a planned mid-2027 NDA filing for crofelemer in MVID, a rare intestinal failure disease.
• Napo will sponsor an intestinal failure panel on Oct. 30, 2026 at a pediatric gastroenterology meeting in Abu Dhabi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610060900ACCESSWRNAPR_____1232993) on October 06, 2026, and is solely responsible for the information contained therein.